Constant Therapeutics Commences Phase 2 Clinical Trial for TXA127 in Ischemic Stroke Recovery with First Patient Dosed
Wednesday, January 10, 2024
Constant Therapeutics LLC, a biopharmaceutical firm specializing in treatments affecting the Alternative Renin-Angiotensin System, has commenced its phase 2 clinical trial for TXA127. This is the company's primary peptide product in development as a potential remedy for ischemic stroke recovery. The initiation of the trial marks the dosing of the first patient in a randomized, placebo-controlled, double-blind, hybrid decentralized study.
The phase 2 trial is crafted to evaluate the safety and effectiveness of TXA127 in individuals aged 18 to 85 who are 6 to 24 months post an ischemic stroke event. The treatment course spans 3 months, and the study, involving 50 participants, is being conducted at Sheba Medical Center in Israel, with collaborative support from Sabar Health for home visits.
Rick Franklin, the CEO of Constant Therapeutics, highlighted the difficulty of organizing clinical trials for chronic stroke patients due to the absence of available medications. He expressed gratitude for the partnership with Sabar Health and Sheba Medical Center, establishing a distinctive infrastructure for evaluating TXA127 in addressing this unmet medical need.
TXA127 is a pharmaceutical formulation of the naturally occurring human peptide angiotensin-(1‐7). Beyond its specific impact on ischemic stroke, TXA127 has exhibited therapeutic potential in animal models for conditions including Duchenne Muscular Dystrophy (DMD), Limb‐Girdle Muscular Dystrophy (LGMD), Congenital Muscular Dystrophy (MDC1A), Marfan Syndrome, and Epidermolysis Bullosa.
Source: prnewswire.com
